Weekly subcutaneous injections of 2.4 mg semaglutide were administered to 902 obese or overweight patients with comorbidities. After a 20-week run-in period, 803 patients achieved the target dose of 2.4mg, and their average body weight decreased from 107.2kg to 96.1kg; subsequently, these patients were randomly divided into two groups, one group received subcutaneous injection of 2.4mg Soma every week glutide, the other group received a placebo for 48 weeks.
The trial met its primary endpoint with statistical significance: Patients randomized to receive semaglutide for 48 weeks had an additional 7.9% reduction in mean body weight from a baseline of 96.1 kg at randomization; An increase of 6.9% from baseline at randomization. Patients who received semaglutide for 68 weeks (20-week lead-in period + 48-week maintenance period) lost an average of 17.4% of their body weight.
The trial met its primary endpoint with statistical significance: Patients randomized to receive semaglutide for 48 weeks had an additional 7.9% reduction in mean body weight from a baseline of 96.1 kg at randomization; An increase of 6.9% from baseline at randomization. Patients who received semaglutide for 68 weeks (20-week lead-in period + 48-week maintenance period) lost an average of 17.4% of their body weight.
